{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:29:58Z","timestamp":1792888198691,"version":"4.5.0"},"reference-count":88,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000650","name":"Institute of Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000650","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012139","name":"Royal Marsden NHS Foundation Trust","doi-asserted-by":"publisher","award":["A28724"],"award-info":[{"award-number":["A28724"]}],"id":[{"id":"10.13039\/100012139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012139","name":"Royal Marsden NHS Foundation Trust","doi-asserted-by":"publisher","award":["RRCOER-Jun24\/100006"],"award-info":[{"award-number":["RRCOER-Jun24\/100006"]}],"id":[{"id":"10.13039\/100012139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006662","name":"National Institute on Handicapped Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C33589\/A28284"],"award-info":[{"award-number":["C33589\/A28284"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.semradonc.2025.04.004","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T19:15:35Z","timestamp":1749755735000},"page":"333-341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Hypofractionation\/Ultra-hypofractionation for Prostate Cancer Radiotherapy"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9511-6844","authenticated-orcid":false,"given":"Deep","family":"Chakrabarti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshani","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Tree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semradonc.2025.04.004_bib0001","article-title":"Cancer statistics, 2025","author":"Siegel","year":"2025","journal-title":"CA A Cancer J Clinicians"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.004_bib0002","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J Clinicians"},{"issue":"9 Suppl","key":"10.1016\/j.semradonc.2025.04.004_bib0003","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1002\/1097-0142(19850501)55:9+<2086::AID-CNCR2820551409>3.0.CO;2-1","article-title":"Biologic basis for altered fractionation schemes","volume":"55","author":"Withers","year":"1985","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.004_bib0004","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0360-3016(82)90517-X","article-title":"Changes in early and late radiation responses with altered dose fractionation: Implications for dose-survival relationships","volume":"8","author":"Thames","year":"1982","journal-title":"Int J Radiat Oncol*Biol*Phys."},{"issue":"740","key":"10.1016\/j.semradonc.2025.04.004_bib0005","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1259\/0007-1285-62-740-679","article-title":"The linear-quadratic formula and progress in fractionated radiotherapy","volume":"62","author":"Fowler","year":"1989","journal-title":"Brit J Radiol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.004_bib0006","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0360-3016(01)01607-8","article-title":"Is \u03b1\/\u03b2 for prostate tumors really low?","volume":"50","author":"Fowler","year":"2001","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.004_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2005.06.009","article-title":"The \u03b1\/\u03b2 ratio for prostate cancer: What is it, really?","volume":"76","author":"Bentzen","year":"2005","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.004_bib0008","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.ijrobp.2010.10.075","article-title":"Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: \u03b1\/\u03b2 = 1.4 (0.9\u20132.2) gy","volume":"82","author":"Miralbell","year":"2012","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.004_bib0009","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ijrobp.2009.10.008","article-title":"Confirmation of a low \u03b1\/\u03b2 ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics","volume":"79","author":"Proust-Lima","year":"2011","journal-title":"Int J Radiat Oncol*Biol*Phys."},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.004_bib0010","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ijrobp.2020.12.041","article-title":"Estimates of alpha\/beta (\u03b1\/\u03b2) ratios for individual late rectal toxicity endpoints: An analysis of the CHHiP trial","volume":"110","author":"Brand","year":"2021","journal-title":"Int J Radiat Oncol*Biol*Phys."},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.004_bib0011","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ijrobp.2022.08.030","article-title":"The fraction size sensitivity of late genitourinary toxicity: Analysis of alpha\/beta (\u03b1\/\u03b2) ratios in the CHHiP trial","volume":"115","author":"Brand","year":"2023","journal-title":"Int J Radiat Oncol*Biol*Phys."},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.004_bib0012","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijrobp.2012.03.004","article-title":"Meta-analysis of the alpha\/beta ratio for prostate cancer in the presence of an overall time factor: Bad news, good news, or No news?","volume":"85","author":"Vogelius","year":"2013","journal-title":"Int J Radiat Oncol*Biol*Phys."},{"issue":"9149","key":"10.1016\/j.semradonc.2025.04.004_bib0013","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0140-6736(98)05180-0","article-title":"Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: A randomised trial","volume":"353","author":"Dearnaley","year":"1999","journal-title":"The Lancet"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.004_bib0014","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1470-2045(07)70143-2","article-title":"Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial","volume":"8","author":"Dearnaley","year":"2007","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.004_bib0015","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(14)70040-3","article-title":"Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: Long-term results from the MRC RT01 randomised controlled trial","volume":"15","author":"Dearnaley","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.004_bib0016","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijrobp.2007.06.054","article-title":"Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer","volume":"70","author":"Kuban","year":"2008","journal-title":"Int J Radiat Oncol*Biol*Phys."},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.004_bib0017","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.ijrobp.2010.03.049","article-title":"70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial","volume":"80","author":"Beckendorf","year":"2011","journal-title":"Int J Radiat Oncol*Biol*Phys."},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.004_bib0018","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.ijrobp.2008.02.073","article-title":"Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer","volume":"72","author":"Al-Mamgani","year":"2008","journal-title":"Int J Radiat Oncol*Biol*Phys."},{"issue":"7","key":"10.1016\/j.semradonc.2025.04.004_bib0019","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1200\/JCO.2009.25.8475","article-title":"Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: Long-term results from Proton Radiation Oncology Group\/American College of Radiology 95-09","volume":"28","author":"Zietman","year":"2010","journal-title":"JCO"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.004_bib0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0039","article-title":"Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: The NRG Oncology RTOG 0126 randomized clinical trial","volume":"4","author":"Michalski","year":"2018","journal-title":"JAMA Oncol"},{"issue":"25","key":"10.1016\/j.semradonc.2025.04.004_bib0021","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1200\/JCO.2005.06.153","article-title":"Randomized trial comparing two fractionation schedules for patients with localized prostate cancer","volume":"23","author":"Lukka","year":"2005","journal-title":"JCO"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.004_bib0022","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.ijrobp.2010.07.1984","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: Final results of phase III randomized trial","volume":"81","author":"Yeoh","year":"2011","journal-title":"Int J Radiat Oncol*Biol*Phys."},{"issue":"20","key":"10.1016\/j.semradonc.2025.04.004_bib0023","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","article-title":"Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer","volume":"34","author":"Lee","year":"2016","journal-title":"JCO"},{"issue":"17","key":"10.1016\/j.semradonc.2025.04.004_bib0024","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"JCO"},{"issue":"8","key":"10.1016\/j.semradonc.2025.04.004_bib0025","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.004_bib0026","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.ijrobp.2012.02.049","article-title":"Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer","volume":"84","author":"Arcangeli","year":"2012","journal-title":"Int J Radiat Oncol*Biol*Phys."},{"issue":"31","key":"10.1016\/j.semradonc.2025.04.004_bib0027","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1200\/JCO.2013.51.1972","article-title":"Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer","volume":"31","author":"Pollack","year":"2013","journal-title":"JCO"},{"issue":"29","key":"10.1016\/j.semradonc.2025.04.004_bib0028","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1200\/JCO.2018.77.9868","article-title":"Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer","volume":"36","author":"Hoffman","year":"2018","journal-title":"JCO"},{"issue":"8","key":"10.1016\/j.semradonc.2025.04.004_bib0029","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(16)30070-5","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial","volume":"17","author":"Incrocci","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.004_bib0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijrobp.2009.07.1691","article-title":"A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer","volume":"78","author":"Arcangeli","year":"2010","journal-title":"Int J Radiat Oncol*Biol*Phys."},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.004_bib0031","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.ijrobp.2014.01.015","article-title":"Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: Results from a randomized trial","volume":"88","author":"Hoffman","year":"2014","journal-title":"Int J Radiat Oncol*Biol*Phys."},{"issue":"17","key":"10.1016\/j.semradonc.2025.04.004_bib0032","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1200\/JCO.2016.70.4189","article-title":"Moderate hypofractionation in high-risk, organ-confined prostate cancer: Final results of a phase III randomized trial","volume":"35","author":"Arcangeli","year":"2017","journal-title":"JCO"},{"issue":"15","key":"10.1016\/j.semradonc.2025.04.004_bib0033","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1200\/JCO.19.01485","article-title":"Ten-year update of a randomized, prospective trial of conventional fractionated versus moderate hypofractionated radiation therapy for localized prostate cancer","volume":"38","author":"Avkshtol","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.004_bib0034","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/j.ijrobp.2024.07.092","article-title":"Hypofractionated, dose-escalated radiation vs. Conventionally fractionated radiation for localized prostate cancer: Long-term update of a phase 3, prospective, randomized controlled trial","volume":"120","author":"Hassanzadeh","year":"2024","journal-title":"Int J Radiat Oncol*Biol*Phys."},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.004_bib0035","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S1470-2045(14)70482-6","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): Acute toxicity results from a randomised non-inferiority phase 3 trial","volume":"16","author":"Aluwini","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.004_bib0036","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(15)00567-7","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): Late toxicity results from a randomised, non-inferiority, phase 3 trial","volume":"17","author":"Aluwini","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.004_bib0037","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ijrobp.2019.09.007","article-title":"Hyprofractionated versus conventionally fractionated radiation therapy for patients with intermediate- or high-risk, localized, prostate cancer: 7-year outcomes from the randomized, multicenter, open-label, phase 3 HYPRO trial","volume":"106","author":"De Vries","year":"2020","journal-title":"Int J Radiat Oncol*Biol*Phys."},{"issue":"20","key":"10.1016\/j.semradonc.2025.04.004_bib0038","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1200\/JCO.23.02445","article-title":"Long-term analysis of NRG Oncology RTOG 0415: A randomized phase III noninferiority study comparing two fractionation schedules in patients with low-risk prostate cancer","volume":"42","author":"Lee","year":"2024","journal-title":"JCO"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.004_bib0039","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.ijrobp.2018.01.016","article-title":"The efficacy and safety of conventional and hypofractionated high-dose radiation therapy for prostate cancer in an elderly population: A subgroup analysis of the CHHiP trial","volume":"100","author":"Wilson","year":"2018","journal-title":"Int J Radiat Oncol*Biol*Phys."},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.004_bib0040","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ijrobp.2020.01.003","article-title":"Derivation of dose\/volume constraints for the anorectum from clinician- and patient-reported outcomes in the CHHiP trial of radiation therapy fractionation","volume":"106","author":"Wilkins","year":"2020","journal-title":"Int J Radiat Oncol*Biol*Phys."},{"issue":"8","key":"10.1016\/j.semradonc.2025.04.004_bib0041","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.clon.2013.05.003","article-title":"Biological dose escalation and hypofractionation: What is there to be gained and how will it best be done?","volume":"25","author":"Tree","year":"2013","journal-title":"Clin Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.004_bib0043","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on prostate Cancer\u20142024 update. Part I: Screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.semradonc.2025.04.004_bib0045","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/14737140.2018.1477595","article-title":"How will the CHHiP trial affect the future of prostate radiotherapy?","volume":"18","author":"Dearnaley","year":"2018","journal-title":"Expert Rev Anticanc Ther"},{"key":"10.1016\/j.semradonc.2025.04.004_bib0046","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/8170428","article-title":"The financial impact of hypofractionated radiation for localized prostate cancer in the United States","volume":"2019","author":"Moore","year":"2019","journal-title":"J Oncol"},{"issue":"11","key":"10.1016\/j.semradonc.2025.04.004_bib0047","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/S1470-2045(24)00407-8","article-title":"Radiotherapy and theranostics: A Lancet Oncology Commission","volume":"25","author":"Abdel-Wahab","year":"2024","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.004_bib0048","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0936-6555(05)80831-3","article-title":"Radical external beam radiotherapy for localised carcinoma of the prostate using a hypofractionation technique","volume":"3","author":"Collins","year":"1991","journal-title":"Clin Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.004_bib0049","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.semradonc.2008.04.005","article-title":"The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery","volume":"18","author":"Kirkpatrick","year":"2008","journal-title":"Semin Radiat Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.004_bib0050","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.semradonc.2008.04.004","article-title":"The linear-quadratic model is an appropriate methodology for determining isoeffective doses at large doses per fraction","volume":"18","author":"Brenner","year":"2008","journal-title":"Semin Radiat Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.004_bib0051","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ijrobp.2013.07.022","article-title":"The tumor radiobiology of SRS and SBRT: Are more than the 5 rs involved?","volume":"88","author":"Brown","year":"2014","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"issue":"10196","key":"10.1016\/j.semradonc.2025.04.004_bib0052","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"The Lancet"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.004_bib0053","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.ijrobp.2006.10.050","article-title":"Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 gy in five fractions for localized disease: First clinical trial results","volume":"67","author":"Madsen","year":"2007","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.004_bib0054","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ijrobp.2010.11.054","article-title":"Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer","volume":"82","author":"King","year":"2012","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"issue":"15","key":"10.1016\/j.semradonc.2025.04.004_bib0055","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1002\/cncr.26699","article-title":"Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: Preliminary results of a multi-institutional phase 1 feasibility trial","volume":"118","author":"McBride","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.semradonc.2025.04.004_bib0056","article-title":"A phase II trial of stereotactic ablative body radiotherapy for low-risk prostate cancer using a non-robotic linear accelerator and real-time target tracking: Report of toxicity, quality of life, and disease control outcomes with 5-year minimum follow-up","volume":"4","author":"Mantz","year":"2014","journal-title":"Front Oncol [Internet]"},{"key":"10.1016\/j.semradonc.2025.04.004_bib0057","article-title":"Predicting biochemical disease-free survival after prostate stereotactic body radiotherapy: Risk-stratification and patterns of failure","volume":"6","author":"Katz","year":"2016","journal-title":"Front Oncol [Internet]"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.004_bib0058","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.radonc.2015.12.020","article-title":"Dose-escalation of five-fraction SABR in prostate cancer: Toxicity comparison of two prospective trials","volume":"118","author":"Musunuru","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2025.04.004_bib0059","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3389\/fonc.2017.00157","article-title":"Prostate-specific antigen 5 years following stereotactic body radiation therapy for low- and intermediate-risk Prostate cancer: An ablative procedure?","volume":"7","author":"Kataria","year":"2017","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.004_bib0060","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.radonc.2018.03.005","article-title":"Dose escalation for prostate stereotactic ablative radiotherapy (SABR): Late outcomes from two prospective clinical trials","volume":"127","author":"Alayed","year":"2018","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.004_bib0061","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijrobp.2018.05.040","article-title":"Multicenter trial of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer: Survival and toxicity endpoints","volume":"102","author":"Meier","year":"2018","journal-title":"Int J Radiat Oncol*Biol*Phys."},{"key":"10.1016\/j.semradonc.2025.04.004_bib0062","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.radonc.2020.04.039","article-title":"Accelerating prostate stereotactic ablative body radiotherapy: Efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT)","volume":"149","author":"Alayed","year":"2020","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.004_bib0063","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jamaoncol.2022.6558","article-title":"Magnetic resonance imaging\u2013Guided vs computed tomography\u2013Guided stereotactic body radiotherapy for prostate cancer: The MIRAGE randomized clinical trial","volume":"9","author":"Kishan","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.semradonc.2025.04.004_bib0064","article-title":"Magnetic resonance imaging versus computed tomography guidance for stereotactic body radiotherapy in prostate cancer: 2-year outcomes from the MIRAGE randomized clinical trial","author":"Kishan","year":"2024","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.004_bib0065","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.8006","article-title":"Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer","volume":"2","author":"Kishan","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"15","key":"10.1016\/j.semradonc.2025.04.004_bib0066","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"Van As","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2025.04.004_bib0067","doi-asserted-by":"crossref","first-page":"S2645","DOI":"10.1016\/S0167-8140(24)03365-6","article-title":"3395: acute toxicity from PACE-C comparing Stereotactic Body Radiotherapy (SBRT) with moderate hypofractionation (MHRT)","volume":"194","author":"Tree","year":"2024","journal-title":"Radiother Oncol"},{"issue":"10","key":"10.1016\/j.semradonc.2025.04.004_bib0068","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.semradonc.2025.04.004_bib0069","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): Acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2025.04.004_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2025.01.014","article-title":"Dosimetric comparison of CyberKnife and conventional linac prostate SBRT plans: Analysis of the PACE-B Study","author":"Ratnakumaran","year":"2025","journal-title":"Int J Radiat Oncol*Biol*Phys."},{"issue":"7","key":"10.1016\/j.semradonc.2025.04.004_bib0071","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: Results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"JCO"},{"key":"10.1016\/j.semradonc.2025.04.004_bib0072","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110568","article-title":"Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial","volume":"201","author":"Draulans","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2025.04.004_bib0073","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109713","article-title":"From once-weekly to semi-weekly whole prostate gland stereotactic radiotherapy with focal boosting: Primary endpoint analysis of the multicenter phase II hypo-FLAME 2.0 trial","volume":"185","author":"De Cock","year":"2023","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.004_bib0074","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ijrobp.2022.09.058","article-title":"Standard and hypofractionated dose escalation to intraprostatic tumor nodules in localized prostate cancer: 5-year efficacy and toxicity in the DELINEATE trial","volume":"115","author":"Tree","year":"2023","journal-title":"Int J Radiat Oncol*Biol*Phys."},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.004_bib0075","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijrobp.2024.03.009","article-title":"Simultaneous focal boost with stereotactic radiation therapy for localized intermediate- to high-risk prostate cancer: Primary outcomes of the SPARC phase 2 trial","volume":"120","author":"Yasar","year":"2024","journal-title":"Int J Radiat Oncol*Biol*Phys."},{"key":"10.1016\/j.semradonc.2025.04.004_bib0076","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.radonc.2019.03.002","article-title":"Two StereoTactic ablative radiotherapy treatments for localized prostate cancer (2STAR): Results from a prospective clinical trial","volume":"135","author":"Alayed","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2025.04.004_bib0077","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109503","article-title":"Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion \u2013 Results from the 2SMART phase 2 trial","volume":"181","author":"Ong","year":"2023","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.004_bib0078","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ijrobp.2023.09.032","article-title":"Interim toxicity analysis from the randomized HERMES trial of 2- and 5-fraction magnetic resonance imaging\u2013Guided adaptive prostate radiation therapy","volume":"118","author":"Westley","year":"2024","journal-title":"Int J Radiat Oncol*Biol*Phys."},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.004_bib0079","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ijrobp.2010.10.026","article-title":"Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: Technique, early toxicity, and PSA response","volume":"82","author":"Jabbari","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2025.04.004_bib0080","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1748-717X-8-84","article-title":"Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: Early results","volume":"8","author":"Aluwini","year":"2013","journal-title":"Radiat Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.004_bib0081","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/1533034614566994","article-title":"High-dose robotic stereotactic body radiotherapy in the treatment of patients with prostate cancer: Preliminary results in 26 patients","volume":"15","author":"Pontoriero","year":"2016","journal-title":"Technol Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.004_bib0082","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.euo.2018.06.013","article-title":"Phase 2 multicenter trial of heterogeneous-dosing stereotactic body radiotherapy for low- and intermediate-risk prostate cancer: 5-year outcomes","volume":"1","author":"Fuller","year":"2018","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.004_bib0083","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13014-022-02037-y","article-title":"A phase II trial of stereotactic body radiotherapy in 4 fractions for patients with localized prostate cancer","volume":"17","author":"Kawakami","year":"2022","journal-title":"Radiat Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.004_bib0084","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijrobp.2021.03.027","article-title":"Toxicity at 1 year after stereotactic body radiation therapy in 3 fractions for localized prostate cancer","volume":"111","author":"Magli","year":"2021","journal-title":"Int J Radiat Oncol*Biol*Phys."},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.004_bib0085","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1001\/jamaoncol.2021.0039","article-title":"Safety and efficacy of virtual prostatectomy with single-dose radiotherapy in patients with intermediate-risk prostate cancer: Results from the PROSINT phase 2 randomized clinical trial","volume":"7","author":"Greco","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.semradonc.2025.04.004_bib0086","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.radonc.2019.07.018","article-title":"Single fraction urethra-sparing prostate cancer SBRT: Phase I results of the ONE SHOT trial","volume":"139","author":"Zilli","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2025.04.004_bib0087","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110181","article-title":"ONE SHOT - single shot radiotherapy for localized prostate cancer: 18-month results of a single arm, multicenter phase I\/II trial","volume":"194","author":"Zilli","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2025.04.004_bib0088","doi-asserted-by":"crossref","first-page":"S770","DOI":"10.1016\/S0167-8140(23)08750-9","article-title":"OC-0924 prostate RT In high risk or N+ moderate vs extreme hypofractionation (PRIME): An interim analysis","volume":"182","author":"Murthy","year":"2023","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.004_bib0089","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1186\/s12885-023-11430-z","article-title":"A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT)","volume":"23","author":"Wolfe","year":"2023","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.004_bib0090","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1186\/s12885-024-12165-1","article-title":"SABR-Dual: A phase II\/III trial of two-fraction versus five-fraction stereotactic radiotherapy for localized low- and favorable intermediate-risk prostate cancer","volume":"24","author":"Fredman","year":"2024","journal-title":"BMC Cancer"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429625000323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429625000323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T15:16:40Z","timestamp":1762355800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053429625000323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":88,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1053429625000323"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.04.004","relation":{},"ISSN":["1053-4296"],"issn-type":[{"value":"1053-4296","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypofractionation\/Ultra-hypofractionation for Prostate Cancer Radiotherapy","name":"articletitle","label":"Article Title"},{"value":"Seminars in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}